QSI$1.30+3.17%
Quantum-Si Inc
Sector: Measuring & Controlling Devices, NECIndustry: Medical - DevicesCountry: USExchange: Nasdaq
Mkt Cap:$284.55M
Float & O/S:174.78M / 218.88M
Inst Own:23.9%
DilutionScan read 43 of Quantum-Si Inc's SEC filings and found 3 warrant series, 2 ATM programs and 2 shelf registrations on file for QSI. The latest dilution event on file is ATM sales on Jun 30, 2026. Analysis updated Nov 4, 2026.
Signal8 Summary
QSI
Pre-revenue burn, Nasdaq delisting risk
Snapshot
Quantum-Si is a pre-revenue-stage life sciences company still developing its main product. FY 2025 revenue was just $2.4M, down 20% YoY, while the company lost $101.3M and burned $97.2M in free cash flow.
What's Happening Right Now
- : Quantum-Si presented interim data claiming its next-generation Proteus platform outperforms its current Platinum Pro instrument, but the system is not yet commercially launched.
- : Founder Jonathan Rothberg and family trusts adopted a 10b5-1 plan to sell up to 8.9 million QSI shares starting January 15, 2027.
- : Q2 2026 revenue fell 41.8% YoY to $344K with a $23.5M net loss; the company cut about 20% of its workforce and pushed its Proteus product launch from late 2026 to Q2 2027.
- : Management says cost cuts push modeled cash runway into Q4 2028 and reiterated full-year 2026 revenue guidance of about $1.0 million.
- : Nasdaq notified Quantum-Si it's out of compliance with the $1.00 minimum bid price rule, giving it until January 19, 2027 to fix it.
